Are there tests (e.g., in vitro testing on tissue), or biomarkers that could help influence the decision? Or other...
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Tests and Biomarkers That Could Guide Josh's Treatment Decisions
Based on Josh's clinical summary, there are several important testing and biomarker considerations that could help inform his next steps:
Available Tissue Resources
The document specifically notes that tissue from Josh's recent splenectomy (September 2025) is available for molecular testing. This is a significant resource that hasn't been fully utilized yet. The summary recommends "molecular profiling of available tissue samples to guide treatment decisions."
Current Biomarker Information
The document confirms Josh has BCL-6 pathway involvement (which is why he was enrolled in the BCL-6 degrader trial). However, the summary notes an important gap:
"Specific genomic mutations, BRCA status, IHC results, and methylation data not provided in available records"
This means comprehensive molecular testing could reveal:
- Additional genetic mutations that might respond to targeted therapies
- Protein expression patterns (immunohistochemistry/IHC) that could identify new treatment targets
- Epigenetic changes that might be actionable
Key Consideration from the Document
The upcoming biopsy scheduled for [date removed] is critical. The summary recommends coordinating "tissue allocation for research testing" — meaning Josh should discuss with his care team how to maximize what can be learned from this biopsy.
Important Next Step
According to NCCN Guidelines for Non-Hodgkin's Lymphomas, comprehensive molecular profiling is recommended for relapsed/refractory disease to identify potential treatment targets. Josh should ask his oncology team specifically about:
- What molecular testing will be performed on the November biopsy
- How results might open new treatment pathways beyond the recommended allogeneic transplant
Would you like me to discuss what specific tests are typically recommended for relapsed follicular lymphoma?
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with diagnosis for cancer patients
Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...
TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2